CARMAT Announces the Approval of All Resolutions Supported b

The company confirms its sales target of €10-13 million for 2023 Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world's most advanced total artificial heart

Related Keywords

France , Villacoublay , France General , Bois Darcy , Bourgogne , Paris , United States , French , Alexandre Conroy , Enregistrement Universel , Caroline Carmagnol , Dusan Oresansky , Laurent Kirsch , Food Drug Administration , Linkedin , European Union , Combined General Meeting , Therabel Invest , Regulated Information General Meetings , French Medtech , Early Feasibility Study , Euronext Growth , Universal Registration Document , Des March , Financial Officer , Gefallene Big Techs , Carmat , Nnounces , Approval , Resolutions , Upported , Board , Directors , Nnual , Eneral , Meeting ,